Endonovo Therapeutics (ENDV) Net Cash Flow (2018 - 2023)
Endonovo Therapeutics has reported Net Cash Flow over the past 12 years, most recently at -$32602.0 for Q3 2023.
- Quarterly results put Net Cash Flow at -$32602.0 for Q3 2023, down 240.9% from a year ago — trailing twelve months through Sep 2023 was -$23139.0 (down 232.93% YoY), and the annual figure for FY2022 was -$85838.0, down 218.37%.
- Net Cash Flow for Q3 2023 was -$32602.0 at Endonovo Therapeutics, down from $48504.0 in the prior quarter.
- Over the last five years, Net Cash Flow for ENDV hit a ceiling of $490924.0 in Q2 2019 and a floor of -$542493.0 in Q3 2019.
- Median Net Cash Flow over the past 5 years was -$2806.0 (2021), compared with a mean of -$19856.8.
- Peak annual rise in Net Cash Flow hit 1873.95% in 2019, while the deepest fall reached 6359.5% in 2019.
- Endonovo Therapeutics' Net Cash Flow stood at $13856.0 in 2019, then decreased by 21.79% to $10837.0 in 2020, then soared by 640.09% to $80204.0 in 2021, then crashed by 128.73% to -$23041.0 in 2022, then plummeted by 41.5% to -$32602.0 in 2023.
- The last three reported values for Net Cash Flow were -$32602.0 (Q3 2023), $48504.0 (Q2 2023), and -$16000.0 (Q1 2023) per Business Quant data.